```text

Wiki Article

Abciximab (C7E3, 143653-53-6): A Research Reagent Overview

Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable scientific substance extensively utilized in platelet studies . This monoclonal antibody fragment selectively targets the glycoprotein IIb/IIIa receptor on platelets , blocking clot formation . Therefore , it's often applied as a method to analyze the mechanisms underlying coagulation and to evaluate the performance of anticoagulant medications . Supply is typically limited to academic settings.

```

Abciximab Drug Research: Utilizing C7E3 and The 143653-53-6 Substance in Scientific Assessments

Ongoing investigation into abciximab, a platelet aggregation inhibitor, frequently utilizes the monoclonal antigen C7E3 and the substance identified as 143653-53-6. These reagents are crucial for investigating abciximab's mechanism of action, evaluating its therapeutic effect in different patient populations, and understanding potential indicators of patient outcome. Continued investigation leveraging these particular reagents is predicted to generate valuable data for optimizing clinical applications related to cardiovascular illness.

```text

C7E3 Abciximab (143653-53-6) - Applications in Scientific Research

C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion Abciximab for research injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }

```

```text

Exploring Potential Possibilities with Abciximab 143653-53-6 and C7E3

Recent work suggest that the drug (identified as 143653-53-6) offers significant research potential, particularly when paired with C7E3. Initial reports suggested that this pairing could enhance clinical responses in several heart-related conditions. Further examination is centered on elucidating the specific mechanism of interaction between the antiplatelet medication and C7E3, encompassing analysis of blood clot cohesion and vascular protection.

  • Ongoing investigation efforts intend to maximize administration strategies.
  • Preclinical systems are were employed to more assess the theories.
  • Patient assessments will be essential to completely assess patient efficacy.

```

Abciximab (C7E3) for Research: Purity and Details (143653-53-6)

Researchers requiring abciximab for laboratory studies should carefully consider integrity and precise parameters . This product is typically provided as a lyophilized powder and thorough analytical information including identity by LC-MS, potency assays, and bacterial endotoxin testing is available. Ensure the source’s documentation outlines required values for related substances and fulfills established quality assurance guidelines.

Pharmaceutical-Grade Abciximab Details & Availability

Acquiring laboratory-grade Abciximab, specifically referencing the compound C7E3 and identified by the chemical number 143653-53-6, requires detailed consideration of its origin . This antibody is widely utilized in cell-based studies , particularly those focused on platelet aggregation and thrombosis . Existing sources offer this substance in varying amounts , typically ranging from mg to significant bulk supplies. Kindly suggest reviewing the certificate of analysis to verify integrity and suitability for your specific use . Furthermore , confirm the stability date before purchasing to maintain optimal effectiveness.

  • Typical Purity: >95%
  • Keeping Conditions: -20°C or suitable conditions
  • Application : Platelet Aggregation Blocking Studies

Report this wiki page